160 related articles for article (PubMed ID: 30192392)
21. Pegylated interferon plus optimized weight-based ribavirin dosing negate the influence of weight and body mass index on early viral kinetics and sustained virological response in chronic hepatitis C.
Pattullo V; Ravindran NC; Mazzulli T; Wong DK; Heathcote EJ
J Viral Hepat; 2010 Dec; 17(12):834-8. PubMed ID: 20196800
[TBL] [Abstract][Full Text] [Related]
22. IL28B gene polymorphisms and viral kinetics in HIV/hepatitis C virus-coinfected patients treated with pegylated interferon and ribavirin.
Rallón NI; Soriano V; Naggie S; Restrepo C; Goldstein D; Vispo E; McHutchison J; Benito JM
AIDS; 2011 May; 25(8):1025-33. PubMed ID: 21505315
[TBL] [Abstract][Full Text] [Related]
23. Is the rapid virologic response a positive predictive factor of sustained virologic response in all pretreatment status genotype 1 hepatitis c patients treated with peginterferon-alpha2b and ribavirin?
de Segadas-Soares JA; Villela-Nogueira CA; Perez RM; Nabuco LC; Brandão-Mello CE; Coelho HS
J Clin Gastroenterol; 2009 Apr; 43(4):362-6. PubMed ID: 19077732
[TBL] [Abstract][Full Text] [Related]
24. Early identification of achieving a sustained virological response in chronic hepatitis C patients without a rapid virological response.
Huang CF; Yang JF; Huang JF; Dai CY; Chiu CF; Hou NJ; Hsieh MY; Lin ZY; Chen SC; Hsieh MY; Wang LY; Chang WY; Chuang WL; Yu ML
J Gastroenterol Hepatol; 2010 Apr; 25(4):758-65. PubMed ID: 20492331
[TBL] [Abstract][Full Text] [Related]
25. Early identification of HCV genotype 1 patients responding to 24 weeks peginterferon alpha-2a (40 kd)/ribavirin therapy.
Jensen DM; Morgan TR; Marcellin P; Pockros PJ; Reddy KR; Hadziyannis SJ; Ferenci P; Ackrill AM; Willems B
Hepatology; 2006 May; 43(5):954-60. PubMed ID: 16628671
[TBL] [Abstract][Full Text] [Related]
26. Twenty-four weeks of pegylated interferon plus ribavirin effectively treat patients with HCV genotype 6a.
Zhou YQ; Wang XH; Hong GH; Zhu Y; Zhang XQ; Hu YJ; Mao Q
J Viral Hepat; 2011 Aug; 18(8):595-600. PubMed ID: 21105968
[TBL] [Abstract][Full Text] [Related]
27. Strategies for assignment of HIV-HCV genotype-1-coinfected patients to either dual-therapy or direct-acting antiviral agent-based triple-therapy.
Mandorfer M; Neukam K; Rivero A; Puoti M; Boesecke C; Baumgarten A; Grzeszczuk A; Zangerle R; Ernst D; Rockstroh JK; Trauner M; Pineda JA; Peck-Radosavljevic M; Reiberger T
Antivir Ther; 2014; 19(4):407-14. PubMed ID: 24342953
[TBL] [Abstract][Full Text] [Related]
28. Virological responses during treatment for recent hepatitis C virus: potential benefit for ribavirin use in HCV/HIV co-infection.
Grebely J; Hellard M; Applegate T; Petoumenos K; Yeung B; Feld JJ; Rawlinson W; Lloyd AR; George J; Kaldor JM; Dore GJ; Matthews GV;
AIDS; 2012 Aug; 26(13):1653-61. PubMed ID: 22555168
[TBL] [Abstract][Full Text] [Related]
29. Pegylated interferon plus ribavirin is suboptimal in IL28B CC carriers without rapid response.
Neukam K; Barreiro P; Rivero-Juárez A; Caruz A; Mira JA; Camacho A; Macías J; Rivero A; Soriano V; Pineda JA
J Infect; 2013 Jul; 67(1):59-64. PubMed ID: 23542783
[TBL] [Abstract][Full Text] [Related]
30. Increased Th1, Th17 and pro-fibrotic responses in hepatitis C-infected patients are down-regulated after 12 weeks of treatment with pegylated interferon plus ribavirin.
Jimenez-Sousa MA; Almansa R; de la Fuente C; Caro-Paton A; Ruiz L; Sanchez-Antolín G; Gonzalez JM; Aller R; Alcaide N; Largo P; Resino S; de Lejarazu RO; Bermejo-Martin JF
Eur Cytokine Netw; 2010 Jun; 21(2):84-91. PubMed ID: 20483710
[TBL] [Abstract][Full Text] [Related]
31. Virological response in patients with hepatitis C virus genotype 1b and a high viral load: impact of peginterferon-alpha-2a plus ribavirin dose reductions and host-related factors.
Yamada G; Iino S; Okuno T; Omata M; Kiyosawa K; Kumada H; Hayashi N; Sakai T
Clin Drug Investig; 2008; 28(1):9-16. PubMed ID: 18081356
[TBL] [Abstract][Full Text] [Related]
32. Antiviral regimen complexity index as an independent predictor of sustained virologic response in patients with chronic hepatitis C.
Galán RJ; Cidoncha EC; Martin MF; Rodriguez CC; Almeida CV; Verdugo RM
J Manag Care Pharm; 2013; 19(6):448-53. PubMed ID: 23806058
[TBL] [Abstract][Full Text] [Related]
33. Role of HCV-RNA decay and IP-10 levels after 48 hours of standard HCV therapy as predictors of rapid virological response.
Prinapori R; Sticchi L; Alicino C; Del Puente F; Mazzarello G; Alessandrini A; Signori A; Icardi G; Bruzzone B; Viscoli C; Di Biagio A
Clin Res Hepatol Gastroenterol; 2015 Dec; 39(6):705-10. PubMed ID: 26070571
[TBL] [Abstract][Full Text] [Related]
34. Telaprevir can be successfully and safely used to treat older patients with genotype 1b chronic hepatitis C.
Furusyo N; Ogawa E; Nakamuta M; Kajiwara E; Nomura H; Dohmen K; Takahashi K; Satoh T; Azuma K; Kawano A; Tanabe Y; Kotoh K; Shimoda S; Hayashi J;
J Hepatol; 2013 Aug; 59(2):205-12. PubMed ID: 23542346
[TBL] [Abstract][Full Text] [Related]
35. The comparison of the efficacy of pegylated interferon α-2a and α-2b in chronic hepatitis C patients with genotype 1.
Dogan UB; Atabay A; Akin MS; Yalaki S
Eur J Gastroenterol Hepatol; 2013 Sep; 25(9):1082-5. PubMed ID: 23524524
[TBL] [Abstract][Full Text] [Related]
36. HCV genotype 1a shows a better virological response to antiviral therapy than HCV genotype 1b.
Pellicelli AM; Romano M; Stroffolini T; Mazzoni E; Mecenate F; Monarca R; Picardi A; Bonaventura ME; Mastropietro C; Vignally P; Andreoli A; Marignani M; D'Ambrosio C; Miglioresi L; Nosotti L; Mitidieri O; Gentilucci UV; Puoti C; Barbaro G; Barlattani A; Furlan C; Barbarini G;
BMC Gastroenterol; 2012 Nov; 12():162. PubMed ID: 23157720
[TBL] [Abstract][Full Text] [Related]
37. Relationship between HCV dynamics and sustained virological responses in chronic hepatitis C genotype 1b patients treated with telaprevir-based triple therapy.
Nakagawa A; Atsukawa M; Tsubota A; Shimada N; Abe H; Kondo C; Itokawa N; Arai T; Hashimoto S; Matsushita Y; Fukuda T; Nakatsuka K; Iwakiri K; Kawamoto C; Aizawa Y; Sakamoto C
Eur J Gastroenterol Hepatol; 2014 Dec; 26(12):1329-34. PubMed ID: 25357216
[TBL] [Abstract][Full Text] [Related]
38. Early viral kinetics during hepatitis C virus genotype 6 treatment according to IL28B polymorphisms.
Akkarathamrongsin S; Payungporn S; Thong VD; Poovorawan K; Prapunwattana P; Poovorawan Y; Tangkijvanich P
World J Gastroenterol; 2014 Aug; 20(30):10599-605. PubMed ID: 25132781
[TBL] [Abstract][Full Text] [Related]
39. Role of interleukin-28B polymorphisms in the treatment of hepatitis C virus genotype 2 infection in Asian patients.
Yu ML; Huang CF; Huang JF; Chang NC; Yang JF; Lin ZY; Chen SC; Hsieh MY; Wang LY; Chang WY; Li YN; Wu MS; Dai CY; Juo SH; Chuang WL
Hepatology; 2011 Jan; 53(1):7-13. PubMed ID: 21254157
[TBL] [Abstract][Full Text] [Related]
40. Combination therapy of peginterferon and ribavirin for chronic hepatitis C patients with genotype 1b and low-virus load.
Arase Y; Suzuki F; Akuta N; Sezaki H; Suzuki Y; Kawamura Y; Kobayashi M; Hosaka T; Yatsuji H; Hirakawa M; Saito S; Ikeda K; Kobayashi M; Kumada H
Intern Med; 2009; 48(5):253-8. PubMed ID: 19252344
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
